bexarotene has been researched along with Invasiveness, Neoplasm in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Akasov, R; Akimov, MG; Bezuglov, VV; Burov, S; Dudina, PV; Gamisonia, AM; Gretskaya, NM; Markvicheva, E; Serkov, IV; Sherstyanykh, G; Zakharov, SS | 1 |
| Cecil, DL; Disis, ML; Gad, E; Herendeen, DR; Lai, VP; Lubet, RA; O'Meara, MM; Park, KH; Treuting, PM | 1 |
| Bode, AM; Chen, H; Dong, Z; Kim, JE; Kim, MS; Lim, DY; Lubet, RA | 1 |
| Chen, G; Chen, K; Fu, S; Jia, L; Jiang, X; Li, H; Li, Y; Liu, X; Ren, Y; Wang, L; Wang, S; Wu, C; Yang, J | 1 |
| Amitay-Laish, I; David, M; Hodak, E | 1 |
| Balitrand, N; Boelle, PY; Cassinat, B; Chomienne, C; Cras, A; Darsin-Bettinger, D; Politis, B; Toubert, ME | 1 |
| Lamph, WW; Yen, WC | 1 |
| DiPette, D; Guleria, R; Joshi, S; Pan, J; Singh, US | 1 |
1 trial(s) available for bexarotene and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer.
Topics: Antigens, Differentiation; Antineoplastic Agents; Bexarotene; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; E1A-Associated p300 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Isotretinoin; Male; Middle Aged; Neoplasm Invasiveness; NF-kappa B; Receptors, Retinoic Acid; Retinoid X Receptor gamma; Tetrahydronaphthalenes; Thyroid Neoplasms; Transcription, Genetic; Transcriptional Activation; Treatment Outcome; Tretinoin | 2012 |
7 other study(ies) available for bexarotene and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Novel bexarotene derivatives: Synthesis and cytotoxicity evaluation for glioma cells in 2D and 3D in vitro models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bexarotene; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Glioma; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasm Invasiveness; Rats; Spheroids, Cellular; Structure-Activity Relationship | 2020 |
A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.
Topics: Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Female; Insulin-Like Growth Factor Binding Protein 2; Lapatinib; Lymphocytes, Tumor-Infiltrating; Mammary Neoplasms, Animal; Mice; Mice, Transgenic; Neoplasm Invasiveness; Precancerous Conditions; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; T-Lymphocytes; Tetrahydronaphthalenes; Tumor Cells, Cultured; Vaccines, Subunit | 2013 |
Src is a novel potential off-target of RXR agonists, 9-cis-UAB30 and Targretin, in human breast cancer cells.
Topics: Bexarotene; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Fatty Acids, Unsaturated; Female; Humans; Matrix Metalloproteinase 9; MCF-7 Cells; Naphthalenes; Neoplasm Invasiveness; Oncogene Protein pp60(v-src); Proto-Oncogene Proteins c-akt; Retinoid X Receptors; Ribosomal Protein S6 Kinases, 70-kDa; Tetrahydronaphthalenes | 2015 |
Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.
Topics: Aged; Animals; Antineoplastic Agents; Bexarotene; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase 1; Histones; HL-60 Cells; Human Umbilical Vein Endothelial Cells; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Middle Aged; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Retinoid X Receptor alpha; RNA, Small Interfering; Tetrahydronaphthalenes; Up-Regulation; Vascular Endothelial Growth Factor A | 2015 |
Systemic progression following complete cutaneous remission under bexarotene treatment for tumor-stage mycosis fungoides.
Topics: Bexarotene; Biopsy, Needle; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Immunohistochemistry; Male; Middle Aged; Mycosis Fungoides; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retreatment; Risk Assessment; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2009 |
The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bexarotene; Breast Neoplasms; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Retinoid X Receptors; Survival Rate; Tetrahydronaphthalenes; Umbilical Veins | 2005 |
Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells.
Topics: Alitretinoin; Antineoplastic Agents; Bexarotene; Cell Differentiation; Cell Movement; Cell Proliferation; Cells, Cultured; Gene Expression Regulation, Neoplastic; GTP-Binding Proteins; Humans; Kidney; Neoplasm Invasiveness; Neuroblastoma; Protein Glutamine gamma Glutamyltransferase 2; Receptors, Retinoic Acid; Retinoid X Receptors; Signal Transduction; Tetrahydronaphthalenes; Transglutaminases; Tretinoin | 2006 |